First-line therapy with Dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma


Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor.
The goal of a study was to evaluate the frontline therapy in advanced penile squamous cell carcinoma ( PSCC ), for which chemotherapy exerts moderate activity but poor efficacy.

In a phase 2 study, patients received Dacomitinib 45 mg/day, orally, continuously. Inclusion criteria were SCC histology, clinical stage N2-3 or M1 ( Tumour-Node-Metastasis classification system 2009 ), and no prior chemotherapy administration.

The primary endpoint was the objective response rate ( ORR, according to RECIST, version 1.1 ).

During the period 2013-2016, 28 patients were treated. Eight ( 28.6% ) had visceral metastases, 14 ( 50% ) had pelvic and 17 ( 60.7% ) clinically involved bilateral lymph nodes.

One complete and eight partial responses were obtained ( ORR 32.1%, 80% credibility interval 21.0-43.0% ).

The median ( interquartile range [ IQR ] ) follow-up duration was 19.8 ( 6.3-25.7 ) months; 12-month progression-free survival was 26.2% ( 95% confidence interval [ CI ] 13.2-51.9 ); 12-month overall survival ( OS ) was 54.9% ( 95% CI 36.4-82.8 ).
The median ( IQR ) overall survival of locally advanced patients was 20 ( 11.1-not reached ) months.

The Bayesian PP of exceeding the 20% ORR target was 92.3%.

Grade 3 adverse events ( skin rash ) were seen in three patients ( 10.7% ).

Tissue samples from 25 patients were analysed. Only two patients had high-risk human papillomavirus-positive tumours.
Epidermal growth factor receptor ( EGFR ) amplification was found in four patients ( equally responders and non-responders ) and it was confirmed in all post-Dacomitinib samples.
Telomerase reverse transcriptase ( TERT ) mutations were found in responders only ( 60% ), and phosphatidylinositol 3-kinase/mammalian target of rapamycin ( PI3K/mTOR ) pathway gene mutations were found in 42.9% of responders vs 8.3% of non-responders.

In conclusion, Dacomitinib was active and well tolerated in patients with advanced penile squamous cell carcinoma and may represent an option when combined chemotherapy cannot be administered.
Mutations in downstream effectors of EGFR signalling in relation to Dacomitinib activity deserve further studies. ( Xagena )

Necchi A et al, BJU Int 2018;121:348-356

Xagena_Medicine_2018



Indietro

Altri articoli

UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...


Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...


In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ),...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a...


HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic...


Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at...


A small number of cases of complex regional pain syndrome following vaccination have been reported to the TGA ( Therapeutic...


Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination...